期刊
CANCER LETTERS
卷 302, 期 1, 页码 54-62出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.12.013
关键词
Chemokine; Granulocyte chemotactic protein-2 (GCP-2); Melanoma
类别
资金
- Centers of Excellence of the K.U. Leuven [EF/05/15]
- Concerted Research Actions (G.O.A.) of the Regional Government of Flanders
- Fund for Scientific Research of Flanders (F.W.O. Vlaanderen)
- Fonds National de la Recherche Scientifique Medicale (FRSM, Belgique)
- European Union [INNOCHEM]
- Interuniversity Attraction Poles Program (I.A.P.)-Belgian Science Policy
The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据